AxoGen's prelim Q4 revenue beats expectations on strong portfolio performance

Reuters01-12
AxoGen's prelim Q4 revenue beats expectations on strong portfolio performance

Overview

  • Peripheral nerve repair firm's preliminary Q4 revenue rose 21.3%, beating analyst expectations

  • Company's revenue growth driven by strong product performance and strategic execution

  • FDA approval of Avance impacted gross margin with one-time costs

Result Drivers

  • PRODUCT PERFORMANCE - Strong performance across AxoGen's product portfolio drove Q4 revenue growth

  • STRATEGIC EXECUTION - Improved execution of commercial strategy targeting high-potential accounts contributed to revenue increase

  • FDA APPROVAL IMPACT - FDA approval of Avance led to one-time costs affecting gross margin

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$59.90 mln

$58 mln (9 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for AxoGen Inc is $36.50, about 8.9% above its January 9 closing price of $33.51

  • The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 42 three months ago

Press Release: ID:nGNX2Ybtnd

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment